Person
MAZZIOTTI Gherardo
Docenti di ruolo di Ia fascia
Docenti di ruolo di IIa fascia
Attachment (CV)
CV-MAZZIOTTI-22-12-2025.doc (CV completo)
Description
Gherardo Mazziotti is Full Professor of Endocrinology, Delegate of Rector for the Quality, Chief of Quality Committee at Humanitas University, Director of post-graduate programme in Endocrinology and Metabolis, Director of Master’s programme for Bone Specialist at Humanitas University and Head of Metabolic Bone Diseases and Osteoporosis Section in Humanitas Clinical and Research Center, IRCCS Rozzano, Italy.
Education and training
1995: Medical degree cum laude, University of Campania Luigi Vanvitelli in Naples, Italy
2000: Specialization in Endocrinology and Metabolism cum laude, University of Campania Luigi Vanvitelli in Naples, Italy
2002-2003: Fellowship, Autoimmunity Section of the Department of Medicine, University of Wales College of Medicine in Cardiff, Galles, UK.
2004: PhD in General Pathology University of Campania Luigi Vanvitelli in Naples, Italy
2005: post-doctoral PhD on GH and bone at University of Brescia, Italy
2010-2011: post-doc level Master in “Osteoporosi e Malattie Metaboliche Ossee”, University of Brescia, Italy
Professional experience
2008-2019: Consultant in Internal Medicine, Endocrinology and Bone diseases. Department of Medicine of Carlo Poma Hospital, Mantua, Italy.
2010: Member of Editorial Board of Pituitary.
2011-2018: Associate Editor of Endocrine
2011-2013: Member of the Directive Council of the " Italian Society of Endocrinology" section Lombardia.
2011-2015: Member of the Committees of “Endotrials” and “Registers for Endocrine Diseases” of Italian Society of Endocrinology.
2013-2017: Assistant professor of Endocrinology at University of Brescia
2015-2019: Member of Scientific Committee of Italian Society of Endocrinology.
2016-2018: Member of Guidelines Committee of Italian Society for Bone Disease (SIOMMMS)
2017-2019 Chief of Digital Communications Committee of Pituitary Society
2017-2019: Head of Endocrine and Bone Unit, Department of Medicine of Carlo Poma Hospital, Mantua, Italy.
2018: Member of Expert Panel on Bone of European Society of Endocrinology.
2019: Member of Editorial Board of Journal of Endocrinological Investigation
2019: Head of Bone diseases and Osteoporosis Section, Humanitas Clinical and Research Center, IRCCS, Rozzano (MI), Italy
2019: Associate Professor of Endocrinology, Humanitas University, Milan.
2020: Member of Editorial Board of Frontiers Endocrinology
2020: Member of the Scientific Committee of L’Endocrinologo
2020: Member of Osteoporosis task-force of Regione Lombardia
2021: Member of Educational Commitee of the Italian Society of Endocrinology
2021: Member of Scientific Commitee of the Italian Society for Bone Disease (SIOMMMS)
2022: Reviewing Editor of e-Life
2022: Director of Master’s programme for Bone Specialist at Humanitas University
2023: Associate Editor of Journal of Endocrinological Investigation
2023: Delegate of Rector for the Quality and Chief of Quality Committee in Humanitas University
2024: Chief of Bone Club of the Italian Society of Endocrinology
2024: Member of the Board of Directors of the Italian Society for Bone Disease (SIOMMMS)
2024: National Coordinator of Regional activities for the Italian Society for Bone Disease (SIOMMMS)
2025: Director of post-graduate Residency Programme in Endocrinology and Metabolism
Over the last 20 years, Gherardo Mazziotti has carried out seminal studies in the field of bone and mineral metabolism with significant contributions in the knowledge of mechanisms and clinical presentation of skeletal fragility induced by endocrine diseases and endocrine therapies in oncological patients. Three of the main accomplishments of the researches in the bone field have been: 1) the application for the first time of vertebral morphometry for diagnosis of skeletal fragility in patients with osteoporosis related to endocrine disease; 2) the demonstration in humans that pituitary hormones (i.e., thyrotropin and prolactin) may have direct effects on bone and they may directly influence skeletal fragility; 3) impact of body composition on bone quality and fracture risk in subjects exposed to hormone deprivation therapies; 4) the application of artificial intelligence and telemedine in the therapeutic-decision making and management of patients with osteoporosis. Gherardo Mazziotti was also leader author of studies on glucocorticoid-induced osteoporosis and multicenter studies in the oncology field investigating the management of bone metastases from thyroid cancer, the efficacy and safety of non conventional therapeutic schedules in acromegaly, the application of telemedicine in management of anti-osteoporotic therapies, application of artificial intelligence in prediction of fractures risk.
Education and training
1995: Medical degree cum laude, University of Campania Luigi Vanvitelli in Naples, Italy
2000: Specialization in Endocrinology and Metabolism cum laude, University of Campania Luigi Vanvitelli in Naples, Italy
2002-2003: Fellowship, Autoimmunity Section of the Department of Medicine, University of Wales College of Medicine in Cardiff, Galles, UK.
2004: PhD in General Pathology University of Campania Luigi Vanvitelli in Naples, Italy
2005: post-doctoral PhD on GH and bone at University of Brescia, Italy
2010-2011: post-doc level Master in “Osteoporosi e Malattie Metaboliche Ossee”, University of Brescia, Italy
Professional experience
2008-2019: Consultant in Internal Medicine, Endocrinology and Bone diseases. Department of Medicine of Carlo Poma Hospital, Mantua, Italy.
2010: Member of Editorial Board of Pituitary.
2011-2018: Associate Editor of Endocrine
2011-2013: Member of the Directive Council of the " Italian Society of Endocrinology" section Lombardia.
2011-2015: Member of the Committees of “Endotrials” and “Registers for Endocrine Diseases” of Italian Society of Endocrinology.
2013-2017: Assistant professor of Endocrinology at University of Brescia
2015-2019: Member of Scientific Committee of Italian Society of Endocrinology.
2016-2018: Member of Guidelines Committee of Italian Society for Bone Disease (SIOMMMS)
2017-2019 Chief of Digital Communications Committee of Pituitary Society
2017-2019: Head of Endocrine and Bone Unit, Department of Medicine of Carlo Poma Hospital, Mantua, Italy.
2018: Member of Expert Panel on Bone of European Society of Endocrinology.
2019: Member of Editorial Board of Journal of Endocrinological Investigation
2019: Head of Bone diseases and Osteoporosis Section, Humanitas Clinical and Research Center, IRCCS, Rozzano (MI), Italy
2019: Associate Professor of Endocrinology, Humanitas University, Milan.
2020: Member of Editorial Board of Frontiers Endocrinology
2020: Member of the Scientific Committee of L’Endocrinologo
2020: Member of Osteoporosis task-force of Regione Lombardia
2021: Member of Educational Commitee of the Italian Society of Endocrinology
2021: Member of Scientific Commitee of the Italian Society for Bone Disease (SIOMMMS)
2022: Reviewing Editor of e-Life
2022: Director of Master’s programme for Bone Specialist at Humanitas University
2023: Associate Editor of Journal of Endocrinological Investigation
2023: Delegate of Rector for the Quality and Chief of Quality Committee in Humanitas University
2024: Chief of Bone Club of the Italian Society of Endocrinology
2024: Member of the Board of Directors of the Italian Society for Bone Disease (SIOMMMS)
2024: National Coordinator of Regional activities for the Italian Society for Bone Disease (SIOMMMS)
2025: Director of post-graduate Residency Programme in Endocrinology and Metabolism
Over the last 20 years, Gherardo Mazziotti has carried out seminal studies in the field of bone and mineral metabolism with significant contributions in the knowledge of mechanisms and clinical presentation of skeletal fragility induced by endocrine diseases and endocrine therapies in oncological patients. Three of the main accomplishments of the researches in the bone field have been: 1) the application for the first time of vertebral morphometry for diagnosis of skeletal fragility in patients with osteoporosis related to endocrine disease; 2) the demonstration in humans that pituitary hormones (i.e., thyrotropin and prolactin) may have direct effects on bone and they may directly influence skeletal fragility; 3) impact of body composition on bone quality and fracture risk in subjects exposed to hormone deprivation therapies; 4) the application of artificial intelligence and telemedine in the therapeutic-decision making and management of patients with osteoporosis. Gherardo Mazziotti was also leader author of studies on glucocorticoid-induced osteoporosis and multicenter studies in the oncology field investigating the management of bone metastases from thyroid cancer, the efficacy and safety of non conventional therapeutic schedules in acromegaly, the application of telemedicine in management of anti-osteoporotic therapies, application of artificial intelligence in prediction of fractures risk.
Overview
Over the last 20 years, Gherardo Mazziotti has carried out seminal studies in the field of bone and mineral metabolism with significant contributions in the knowledge of mechanisms and clinical presentation of skeletal fragility induced by endocrine diseases and endocrine therapies in oncological patients. Three of the main accomplishments of the researches in the bone field have been: 1) the application for the first time of vertebral morphometry for diagnosis of skeletal fragility in patients with osteoporosis related to endocrine disease; 2) the demonstration in humans that pituitary hormones (i.e., thyrotropin and prolactin) may have direct effects on bone and they may directly influence skeletal fragility; 3) impact of body composition on bone quality and fracture risk in subjects exposed to hormone deprivation therapies; 4) the application of artificial intelligence and telemedine in the therapeutic-decision making and management of patients with osteoporosis. Gherardo Mazziotti was also leader author of studies on glucocorticoid-induced osteoporosis and multicenter studies in the oncology field investigating the management of bone metastases from thyroid cancer, the efficacy and safety of non conventional therapeutic schedules in acromegaly, the application of telemedicine in management of anti-osteoporotic therapies, application of artificial intelligence in prediction of fractures risk. Gherardo Mazziotti has published more than 240 papers in international peer-reviewed journals (more than 12.000 citations, Scopus H-index 58; Scopus ID 6701486206).
No Results Found